Ricevi le ultime notizie sulle azioni Dyne Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di DYN

Ultime notizie per

DYNE THERAPEUTICS INC

Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Dyne Therapeutics Inc

iShares U.S. Equity Factor Rotation Active ETF

Hartford Dynamic Bond ETF

Dye & Durham Ltd

Dynatronics Corp

DynaResource Inc

DYNASTAR HOLDINGS INC by Dynastar Holdings, Inc.

Dynastar Holdings Inc

ETF Opportunities Trust Idx Dynamic Innovation Etf

Dynamix Corp Class A ordinary Shares

Dynamix Corp Unit (1 Ord Class A & 1/2 War)

Dynamix Corp Warrants (25/10/2029)

News

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Health Care

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.  - DYN

Dyne Therapeutics to Present at Upcoming Investor Conferences

Management

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

General

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Biohaven

Celcuity

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Cogent Biosciences

Denali Therapeutics

89bio

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Raymond James

Oppenheimer

Stifel

RBC Capital

Chardan Capital

Dynegy

WIIM

Dyne Therapeutics shares are trading higher. The company announced one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen, in patients with myotonic dystrophy type 1  demonstrating clinically meaningful improvements in function and strength at the selected registrational dose.

Comments

Dyne Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO